文献速递药物相互作用抗栓抗凝管理

维利西呱的药效学与药代动力学相互作用:三项I期随机研究

Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers.
PubMed 文献 · Clin Pharmacokinet · 2021-01-01

三项I期随机研究评估维利西呱与沙库巴曲缬沙坦、阿司匹林或华法林的相互作用。结果显示联用耐受性良好,未观察到有临床意义的药效学或药代动力学相互作用,支持维利西呱与这些心衰常用药物联用且无需调整剂量。

要点

  • 维利西呱与阿司匹林联用不影响出血时间或血小板聚集。
  • 维利西呱与华法林联用不影响华法林抗凝效果。
  • 维利西呱与沙库巴曲缬沙坦联用无临床相关药效学变化且无药代动力学相互作用。

核心结论

  • 维利西呱与沙库巴曲缬沙坦、阿司匹林或华法林联用耐受性良好,未观察到有临床意义的药效学或药代动力学相互作用,支持联用且无需调整剂量。

研究设计与样本

  • 三项I期研究在健康志愿者中评估维利西呱与心衰治疗药物(沙库巴曲缬沙坦、阿司匹林)或窄治疗指数药物(华法林)的安全性、药效学和药代动力学相互作用。

主要发现

  • 维利西呱15 mg单次给药与阿司匹林1000 mg联用对出血时间或血小板聚集无影响,最小二乘均值差异分别为2.7%(95%CI -90.4至95.8)和2.4%(95%CI -7.0至11.8,浊度法)。
  • 维利西呱10 mg每日一次对华法林25 mg单次给药引起的凝血抑制无影响,凝血参数治疗比较的0至96小时血药浓度-时间曲线下面积均值比约为100.0%。
  • 沙库巴曲缬沙坦97/103 mg与维利西呱2.5 mg单次或多次给药或安慰剂联用无临床相关药效学变化,收缩压差异-1.66 mmHg(90%CI -4.22至0.90),舒张压差异-1.80 mmHg(90%CI -3.24至-0.36),心率差异-0.33次/分(90%CI -2.25至1.60)。
  • 维利西呱与阿司匹林、华法林或沙库巴曲缬沙坦联用达稳态时未显示药代动力学相互作用。
  • 所有治疗耐受性良好。

临床怎么用

  • 心衰患者可同时使用维利西呱与沙库巴曲缬沙坦、阿司匹林或华法林,无需调整维利西呱或联用药物的剂量。

局限性

  • 研究在健康志愿者中进行,结论外推至心衰患者需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vericiguat, a direct stimulator of soluble guanylate cyclase, has been developed as a first-in-class therapy for symptomatic chronic heart failure (HF) and ejection fraction < 45%. METHODS: Safety, pharmacodynamic (PD), and pharmacokinetic (PK) interactions between vericiguat and drugs used in HF (sacubitril/valsartan [SV] and aspirin [acetylsalicylic acid]) or with a narrow therapeutic index (warfarin) were evaluated in three phase I studies. RESULTS: Vericiguat 15 mg (single dose [SD]) had no effect on bleeding time or platelet aggregation when coadministered with aspirin 1000 mg versus aspirin alone: estimated differences in least squares means 2.7% (95% confidence interval [CI] - 90.4 to 95.8) and 2.4% (95% CI - 7.0 to 11.8) turbidimetry, respectively. Vericiguat 10 mg (once daily) had no effect on coagulation inhibition elicited by warfarin 25 mg (SD; mean ratios of area under the concentration-time curve from time zero to 96 h for clotting parameter treatment comparisons approximated 100.0%). There were no clinically relevant PD changes whether SV 97/103 mg was administered with single or multiple doses of vericiguat 2.5 mg or placebo (differences in systolic blood pressure [BP] - 1.66 mmHg [90% CI - 4.22 to 0.90]; diastolic BP - 1.80 mmHg [90% CI - 3.24 to - 0.36]; heart rate - 0.33 beats/min [90% CI - 2.25 to 1.60]). Vericiguat demonstrated no PK interactions when coadministered with aspirin, warfarin, or SV at steady state. Treatments were well tolerated. CONCLUSIONS: Coadministration of vericiguat with SV, aspirin, or warfarin was well tolerated. No clinically relevant PD or PK interactions were observed, supporting concomitant use of these drugs, commonly used by patients with HF, with vericiguat and no dose adjustment. EUDRACT NUMBER: 2014-000765-52; 2014-004880-19; 2015-004809-16.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Boettcher M, Loewen S, Gerrits M, et al. Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers. Clin Pharmacokinet. 2021. PMID: 33030703. doi:10.1007/s40262-020-00935-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。